Story perspectives

AstraZeneca Halts volrustomig eVOLVE-Lung02 Trial Over Failing Endpoints

8/17/2026

Summary

Story summary

AstraZeneca halted the eVOLVE-Lung02 trial of volrustomig after the Data Monitoring Committee said it is unlikely to meet progression-free or overall survival endpoints.
The trial enrolled 895 patients in 25 countries with NSCLC PD-L1 < 50% (focus PD-L1-negative <1%) and shares fell about 2% in early trading.
Vice President Susan Galbraith called the result disappointing, pledged to learn, and said other volrustomig trials in cervical, head-and-neck and mesothelioma cancers will continue.

1 of 1

Story summary

AstraZeneca halted the eVOLVE-Lung02 trial of volrustomig after the Data Monitoring Committee said it is unlikely to meet progression-free or overall survival endpoints.
The trial enrolled 895 patients in 25 countries with NSCLC PD-L1 < 50% (focus PD-L1-negative <1%) and shares fell about 2% in early trading.
Vice President Susan Galbraith called the result disappointing, pledged to learn, and said other volrustomig trials in cervical, head-and-neck and mesothelioma cancers will continue.